Shire’s HAE drug Firazyr cleared for children
European regulators have approved a label extension for Shire’s Firazyr, broadening its use include adolescents and children aged two years and older with a particular type of HAE.
Read More
Tag: icatibant
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
